Commodore Capital LP
- SEC CIK
- 0001831942
- Latest filing
- Aug 14, 2026
Holdings in Q2 2024
Holdings as of Jun 30, 2024, filed Aug 14, 2024. Long positions only; changes compare share counts with Q1 2024.
- Positions
- 35
- −4 vs. Q1 2024
- Portfolio value
- $1.47B
- −$30.5M (−2.0%) vs. Q1 2024
| Security | Class | Shares | Value | % of portfolio | Share change | Action | History |
|---|---|---|---|---|---|---|---|
| AVTXAvalo Therapeutics, Inc. | COM NEW | 40,000 | $498.8K | <0.1% | +40,000 | New | History |
| ORKAOruka Therapeutics, Inc. | COM | 414,325 | $1.59M | 0.1% | +414,325 | New | History |
| AUTLAutolus Therapeutics plc | SPON ADS | 1,178,723 | $4.10M | 0.3% | −1,121,277−48.8% | Reduced | History |
| BBOTBridgeBio Oncology Therapeutics, Inc. | CL A ORD SHS | 500,000 | $5.11M | 0.3% | 00.0% | Unchanged | History |
| VTGNVistagen Therapeutics, Inc. | COM | 1,575,000 | $5.48M | 0.4% | 00.0% | Unchanged | History |
| NGNENeurogene Inc. | COM | 200,000 | $7.28M | 0.5% | 00.0% | Unchanged | History |
| FRNMFreenome, Inc. | CL A ORD SHS | 750,000 | $7.54M | 0.5% | +750,000 | New | History |
| CABACabaletta Bio, Inc. | COM | 1,100,000 | $8.23M | 0.6% | 00.0% | Unchanged | History |
| APGEApogee Therapeutics, Inc. | COM | 290,000 | $11.4M | 0.8% | 00.0% | Unchanged | History |
| ORICOric Pharmaceuticals, Inc. | COM | 2,000,000 | $14.1M | 1.0% | 00.0% | Unchanged | History |
| CCCCC4 Therapeutics, Inc. | COM STK | 3,410,384 | $15.8M | 1.1% | 00.0% | Unchanged | History |
| SNDXSyndax Pharmaceuticals Inc | COM | 825,000 | $16.9M | 1.2% | +506,149+158.7% | Added | History |
| ABVXAbivax S.A. | SPONSORED ADS | 1,284,110 | $17.0M | 1.2% | −610,893−32.2% | Reduced | History |
| IMVTImmunovant, Inc. | COM | 750,990 | $19.8M | 1.4% | 00.0% | Unchanged | History |
| THRDThird Harmonic Bio, Inc. | COM | 1,545,426 | $20.1M | 1.4% | +295,426+23.6% | Added | History |
| CELCCelcuity Inc. | COM | 1,464,105 | $24.0M | 1.6% | −91,849−5.9% | Reduced | History |
| NKTXNkarta, Inc. | COM | 4,151,034 | $24.5M | 1.7% | +986,034+31.2% | Added | History |
| KURAKura Oncology, Inc. | COM | 1,593,350 | $32.8M | 2.2% | +68,350+4.5% | Added | History |
| VRDNViridian Therapeutics, Inc. | COM | 2,528,032 | $32.9M | 2.2% | +593,379+30.7% | Added | History |
| ALKSAlkermes plc. | SHS | 1,375,000 | $33.1M | 2.3% | +1,375,000 | New | History |
| PHVSPharvaris N.V. | COM | 1,810,175 | $34.0M | 2.3% | +85,175+4.9% | Added | History |
| CATXPerspective Therapeutics, Inc. | COM NEW | 4,657,345 | $46.4M | 3.2% | +4,657,345 | New | History |
| SYRESpyre Therapeutics, Inc. | COM NEW | 1,988,084 | $46.7M | 3.2% | +104,000+5.5% | Added | History |
| ARVNArvinas, Inc. | COM | 1,884,361 | $50.2M | 3.4% | +609,361+47.8% | Added | History |
| RYTMRhythm Pharmaceuticals, Inc. | COM | 1,225,000 | $50.3M | 3.4% | +175,000+16.7% | Added | History |
| DFTXDefinium Therapeutics, Inc. | Stock | 7,145,888 | $51.5M | 3.5% | +1,312,555+22.5% | Added | History |
| CLDXCelldex Therapeutics, Inc. | COM NEW | 1,425,000 | $52.7M | 3.6% | +558,532+64.5% | Added | History |
| SLNOSoleno Therapeutics Inc | COM | 1,425,000 | $58.1M | 4.0% | +1,255,467+740.5% | Added | History |
| COGTCogent Biosciences, Inc. | COM | 9,738,000 | $82.1M | 5.6% | +3,313,000+51.6% | Added | History |
| VERAVera Therapeutics, Inc. | CL A | 2,475,000 | $89.5M | 6.1% | −690,000−21.8% | Reduced | History |
| ELVNEnliven Therapeutics, Inc. | COM | 3,973,245 | $92.9M | 6.3% | 00.0% | Unchanged | History |
| PCVXVaxcyte, Inc. | COM | 1,305,000 | $98.5M | 6.7% | +445,000+51.7% | Added | History |
| XENEXenon Pharmaceuticals Inc. | COM | 2,754,266 | $107.4M | 7.3% | +586,473+27.1% | Added | History |
| NUVLNuvalent, Inc. | COM | 1,487,756 | $112.9M | 7.7% | 00.0% | Unchanged | History |
| MRUSMerus N.V. | COM | 3,200,000 | $189.3M | 12.9% | −1,160,000−26.6% | Reduced | History |
Sold out since Q1 2024 (9)
Positions held at the end of Q1 2024 that are gone from this filing.
| Security | Class | Shares in Q1 2024 | Value in Q1 2024 | % of portfolio in Q1 2024 | History |
|---|---|---|---|---|---|
| ALPNAlpine Immune Sciences, Inc. | COM | 1,375,000 | $54.5M | 3.6% | History |
| CATXPerspective Therapeutics, Inc. | COM | 21,052,631 | $25.1M | 1.7% | History |
| KYTXKyverna Therapeutics, Inc. | COM | 912,189 | $22.7M | 1.5% | History |
| ENGNenGene Therapeutics Inc. | COM | 1,250,000 | $21.2M | 1.4% | History |
| ADVMAdverum Biotechnologies, Inc. | COM NEW | 657,333 | $9.29M | 0.6% | History |
| MGNXMacrogenics Inc | COM | 295,020 | $4.34M | 0.3% | History |
| ACETAdicet Bio, Inc. | COM | 1,374,320 | $3.23M | 0.2% | History |
| SABSSAB Biotherapeutics, Inc. | COM NEW | 183,174 | $831.6K | 0.1% | History |
| DBVTDBV Technologies S.A. | SPONSORED ADR | 92,687 | $69.4K | <0.1% | History |